Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to CalTech, Engeneic, and More

Premium

Title: Bacterially Derived Intact Minicells That Encompass Plasmid-free Functional Nucleic Acid for In Vivo Delivery to Mammalian Cells

Patent Number: 8,669,101

Filed: Dec. 29, 2010

Lead Inventor: Himanshu Brahmbhatt, Engeneic Molecular Delivery


Title: Polyion Complex of Double-stranded Ribonucleic Acid

Patent Number: 8,668,933

Filed: March 31, 2010

Lead Inventor: Yuichi Hori, University of Tokyo


Title: Biotinylated Compositions

Patent Number: 8,669,236

Filed: May 12, 2006

Lead Inventor: David Elmaleh, Children's Medical Center


Title: Modulation of Innate Immunity Receptors' Signaling by microRNAs miR-146a and miR-146b

Patent Number: 8,669,235

Filed: March 22, 2007

Lead Inventor: David Baltimore, California Institute of Technology

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.